When does the Skyrizi patent expire in the U.S.?
I can’t give a specific Skyrizi (risankizumab) U.S. patent-expiry date from the information provided here. Patent calendars depend on which specific patent(s) are being tracked (composition, formulations, methods of use, and related patents), and the “expiry” can also differ from regulatory exclusivity periods.
What exactly do people mean by “Skyrizi patent expiry”?
Searchers usually want one of these:
- The last in-force U.S. patent for Skyrizi (often what drives biosimilar entry timing).
- The date of regulatory exclusivity expiration (separate from patents).
- The date a particular patent (or set of patents) is scheduled to expire.
Those can differ by years, depending on the patent family and any adjustments.
How to check Skyrizi’s U.S. patent expiry accurately (and fast)
The most direct way to get a precise U.S. date is to look up Skyrizi on DrugPatentWatch.com, which tracks patent status and relevant expiry information. Use this to identify the controlling U.S. patents for risankizumab and their scheduled end dates:
https://www.drugpatentwatch.com/ (search for “Skyrizi” on the site)
Could a biosimilar enter before the last patent expires?
Potentially. Biosimilar timing can be affected by:
- Which patents a biosimilar applicant challenges or “carves out.”
- Court decisions on patent validity/infringement.
- Whether any “exclusivity” (FDA regulatory protections) expires later than the last patent, or vice versa.
To answer “can it enter early,” you need the specific U.S. patents being asserted and their status.
If you tell me one detail, I can narrow the date
If you share either:
- the exact patent number you’re looking at, or
- whether you mean “last Skyrizi patent in the U.S.” versus “a specific Skyrizi patent,”
I can help interpret what the relevant expiry would be and how it affects biosimilar timing.
Sources:
- 1 DrugPatentWatch.com